299 assets in Lung Cancer

Therapeutic assets addressing Lung Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Niraparib Lung Cancer	M.D. Anderson Cancer Center	P2	B (58)
Olaparib Lung Cancer	Sichuan University	P2	B (58)
Panobinostat Lung Cancer	National Cancer Institute (NCI)	P3	B (58)
al2846 Lung Cancer	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P2	B (57)
Brigatinib Lung Cancer	Fundación GECP	P3	B (57)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Lung Cancer	City of Hope Medical Center	P2	B (57)
Memantine Lung Cancer	NRG Oncology	P3	B (57)
Sapanisertib Lung Cancer	M.D. Anderson Cancer Center	P1/2	B (57)
TIL Lung Cancer	Essen Biotech	P2	B (57)
Memantine Hydrochloride Lung Cancer	NRG Oncology	P3	B (56)
Anamorelin Lung Cancer	M.D. Anderson Cancer Center	P2/3	CCC (55)
Cabozantinib Lung Cancer	Jun Zhang, MD, PhD	P2	CCC (55)
Capecitabine Lung Cancer	Odense University Hospital	P2	CCC (55)
Diphenhydramine Lung Cancer	Ciusss de L'Est de l'Île de Montréal	P3	CCC (55)
Indocyanine Green Lung Cancer	M.D. Anderson Cancer Center	P2	CCC (55)
Nogapendekin Alfa Lung Cancer	SWOG Cancer Research Network	P2/3	CCC (55)
Tretinoin Lung Cancer	Peking University People's Hospital	P2	CCC (55)
Zimberelimab Lung Cancer	Gilead Sciences	P2	CCC (55)
Fulvestrant Lung Cancer	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P2	CCC (54)
Avapritinib Lung Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Binimetinib Lung Cancer	N.N. Petrov National Medical Research Center of Oncology	P2	CCC (53)
c105 Lung Cancer	University of Washington	P2	CCC (53)
cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine Lung Cancer	University of Washington	P2	CCC (53)
Cetuximab Sarotalocan Lung Cancer	Roswell Park Cancer Institute	P2	CCC (53)
Cobimetinib Lung Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Dabrafenib Lung Cancer	Sun Yat-sen University	P2	CCC (53)
Danvatirsen Lung Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Diclofenac Lung Cancer	Emory University	P2	CCC (53)
Evolocumab Lung Cancer	Eziafa Oduah, MD, PhD, MPH	P2	CCC (53)
Fianlimab Lung Cancer	Mayo Clinic	P2	CCC (53)
Glecirasib Lung Cancer	Sun Yat-sen University	P2	CCC (53)
gt103 Lung Cancer	Roswell Park Cancer Institute	P2	CCC (53)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Lung Cancer	EMD Serono Research & Development Institute, Inc.	P3	CCC (53)
Ivonescimab Lung Cancer	SWOG Cancer Research Network	P2	CCC (53)
Larotrectinib Lung Cancer	Sun Yat-sen University	P2	CCC (53)
Methoxyamine Lung Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Pevonedistat Lung Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Pralsetinib, Trans- Lung Cancer	Sun Yat-sen University	P2	CCC (53)
Pyrotinib Lung Cancer	Sun Yat-sen University	P2	CCC (53)
Recombinant Human Hyaluronidase Lung Cancer	University of Southern California	P2	CCC (53)
Selpercatinib Lung Cancer	SWOG Cancer Research Network	P2	CCC (53)
Sry-Box Transcription Factor 2 Lung Cancer	University of Washington	P2	CCC (53)
Sunvozertinib Lung Cancer	Sun Yat-sen University	P2	CCC (53)
SX682 Lung Cancer	University of Washington	P2	CCC (53)
Talazoparib Lung Cancer	University Health Network, Toronto	P2	CCC (53)
Tepotinib Lung Cancer	SWOG Cancer Research Network	P2	CCC (53)
Tocilizumab Lung Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Yb-1 Lung Cancer	University of Washington	P2	CCC (53)
Zorifertinib Lung Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
[68ga]cbp8 Lung Cancer	Massachusetts General Hospital	P2	CCC (52)

Showing 51 to 100 of 299 assets

PreviousPage 2 of 6Next